Lindis Blood Care

Executive Summary

Lindis Blood Care, a German MedTech company founded in 2018 and headquartered in Munich, is developing innovative antibody-based medical devices to enhance transfusion safety, particularly during cancer surgeries. The company's initial focus is on removing tumor and immune cells from salvaged blood, addressing the critical need to prevent potential contamination and improve patient outcomes in oncology procedures. By leveraging proprietary antibody technologies, Lindis aims to enable safer autologous transfusions, reducing reliance on donor blood and mitigating risks such as infection or immune reactions. The technology has the potential to expand into other therapeutic areas, including autoimmune diseases and infectious conditions, though the primary application remains perioperative blood management. Lindis Blood Care operates in the MedTech and hematology space, targeting a growing market driven by increasing cancer surgeries and demand for blood conservation strategies. While the company is still in early stages without disclosed funding or valuation, its innovative approach has attracted attention within the biopharma community. Key milestones ahead include advancing preclinical studies, initiating first-in-human trials, and securing regulatory approvals for its devices. The company's success hinges on demonstrating safety and efficacy in removing targeted cells without harming blood quality, as well as establishing manufacturing partnerships. Given the early stage, the conviction is moderate, reflecting the technical and regulatory hurdles typical for novel medical devices.

Upcoming Catalysts (preview)

• Q2 2026First-in-human clinical trial initiation40% success
• Q4 2026Strategic partnership with a major medical device company30% success
• Q3 2026Publication of preclinical data in peer-reviewed journal60% success